| セッション情報 | The 4th International ForumShort Oral Presentations（Pancreaticobiliary disorders 2） |
|---|---|
| タイトル | IF-SOP-20：Investigation of biological characteristics of biliary tract cancers to establish a novel molecular-targeted therapy |
| 演者 | Yokoyama Masaaki（Kyorin University, Japan） |
| 共同演者 | |
| 抄録 | ＜Purpose＞ The purpose of this study is to investigate various genes mutations and protein overexpression in biliary tract cancer（BTC）, in order to establish most optimal molecular targeted therapy. ＜Method＞ In 63 surgical cases of BTC, DNA was extracted from formalin fixed paraffin-embedded sections samples. Various genes mutations（KRAS, BRAF, PIK3CA, Fbxw7）were examined using polymerase chain reaction（PCR）on DNA. Protein revelations（EGFR, HER2, TP53）were also examined by Immunohistochemistry（IHC）. ＜Result＞ Nine mutations were identified within KRAS. The over all survival of KRAS mutation-positive cases was significantly worse than that of KRAS mutation-negative cases（P=0.005）. However, no mutations were identified in BTC within BRAF, PIK3CA, and Fbxw7. EGFR overexpression was found in 5 tumors. EGFR overexpression was associated with early Stage（P=0.027）. HER2 overexpression was found in 14 tumors. HER2 overexpression was occurred in gallbladder cancers more frequently than in bile duct cancers（P=0.035）. ＜Conclusion＞ The KRAS mutation can be a biomarker indicating poor prognostic factor. The usefulness of HER2-targeted agent for HER2-positive gallbladder cancer is suggested. Key word：biliary tract cancer, molecular targeted therapy, mutation, overexpression |
| 索引用語 |